Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Editas Medicine's fourth-quarter earnings exceeded expectations, with the stock rising 2% pre-market
Cambridge, Massachusetts - Editas Medicine Inc. (NASDAQ: EDIT) reported fourth-quarter results that exceeded analyst expectations. The gene editing company’s loss was $0.06 per share, better than the market forecast of a $0.23 loss per share. Revenue reached $24.74 million, significantly surpassing the analyst estimate of $8.02 million but down from $30.60 million in the same period last year.
Following the earnings release, the company’s stock rose 2% in pre-market trading.
The company’s collaboration and other R&D revenue declined 19% year-over-year, mainly due to milestone revenue recognized in Q4 2024 under its partnership agreement with Bristol-Myers Squibb.
Gilmore O’Neill, President and CEO of Editas Medicine, stated, “We made significant progress in Q4 2025, advancing our mission and strategy to become a leader in in vivo gene editing.”
The company reported a net loss of $5.6 million for the quarter, a substantial improvement from a $45.4 million loss in the same period last year.
R&D expenses decreased by $21.2 million to $27.4 million, primarily due to lower clinical and manufacturing costs following the termination of the reni-cel program in December 2024.
General and administrative expenses declined by $5 million to $11.4 million.
At the end of this quarter, Editas held $146.6 million in cash and cash equivalents, down from $269.9 million a year earlier. The company expects its cash position to fund operations through the third quarter of 2027.
The company remains on track to submit an IND/CTA application for its lead candidate, EDIT-401, by mid-2026, and plans to initiate its first human clinical trial for heterozygous familial hypercholesterolemia patients later this year.
Preclinical studies of EDIT-401 showed an average LDL-C reduction of over 90%. Editas expects to obtain early human proof-of-concept data by the end of 2026.
This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.